Patient characteristics
| All patients | |
| N=228 (%) | |
| Median age at diagnosis (range) (years) | 65.5 (23–91) |
| Gender | |
| Male | 154 (67.5) |
| Female | 74 (32.5) |
| Race | |
| White | 224 (98.2) |
| Black or African American | 4 (1.8) |
| Stage | |
| III | 43 (18.9) |
| IV | 185 (81.1) |
| Brain metastases at treatment start | 25 (11.0) |
| History of VTE | 20 (8.8) |
| History of ATE | 9 (3.9) |
| History of CAD | 29 (12.7) |
| Anticoagulation with/without prior DVT at treatment start | 11 (4.8) |
| Khorana Score at treatment start | |
| 0 | 154 (67.5) |
| 1 | 50 (22.0) |
| 2 | 11 (4.8) |
| 3 | 8 (3.5) |
| Unknown | 5 (2.2) |
| ICI type(s) | |
| Ipilimumab | 46 (20.2) |
| Ipilimumab/nivolumab | 67 (29.4) |
| Nivolumab | 28 (12.3) |
| Pembrolizumab | 87 (38.1) |
ATE, arterial thromboembolism; CAD, coronary artery disease; DVT, deep venous thrombosis; VTE, venous thromboembolism.